Bacthera and seres therapeutics collaborate for commercial manufacturing of ser-109, a potential treatment against recurrent c. difficile infection

Basel, switzerland & cambridge, mass. & horsholm, denmark--(business wire)--bacthera, a specialized contract development and manufacturing organization (cdmo), and seres therapeutics, a leading microbiome therapeutics company, announced today a collaboration to manufacture ser-109, seres' lead product candidate for recurrent clostridioides difficile infection (rcdi). under the terms of the agreement, bacthera is establishing a dedicated facility for commercial manufacturing in its new microbiom
MCRB Ratings Summary
MCRB Quant Ranking